L-Citrulline is under clinical development by Asklepion Pharmaceuticals and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect L-Citrulline’s likelihood of approval (LoA) and phase transition for Acute Respiratory Failure took place on 27 Jan 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their L-Citrulline Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

L-Citrulline overview

L-Citrulline is under development for the treatment of acute hypoxemic respiratory failure in patients with COVID-19 (SARS-CoV2) illness, acute post operative lung injury and acute sickle cell crisis. The drug is administered by both intravenous and oral route. It was also under development for prevention of hepatic veno occlusive disease as oral formulation and pulmonary hypertension in children during bypass surgery.

Asklepion Pharmaceuticals overview

Asklepion Pharmaceuticals (Asklepion) is a biopharmaceutical company. It is engaged in the discovery and development of treatments for rare pediatric diseases. The company’s pipeline products include intravenous L-citrulline. The company’s intravenous L-citrulline is used to treat acute post-op lung injury. It also conducts clinical trials to treat children who are undergoing heart bypass surgery. The company partners with universities, pharmaceutical companies, drug distributors, and financial assistance programs to build a foundation for its products. Asklepion is headquartered in Baltimore, Maryland, the US.

Quick View L-Citrulline LOA Data

Report Segments
  • Innovator
Drug Name
  • L-Citrulline
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Hematological Disorders
  • Infectious Disease
  • Respiratory
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.